Stock Price & Analysis

Based on the technical indicators and recent analyst coverage, GMAB stock appears to be a hold at current levels. The stock is showing overbought signals with RSI above 65 and stochastic readings near 97, suggesting potential short-term pullback, though the positive MACD indicates some remaining upward momentum.

Recent analyst coverage maintains mixed views, with TD Cowen keeping a Hold rating at a $22.34 price point, while Truist Financial maintains a Buy rating with potential upside to their $34.25 price target. The recent upgrade by Leerink Partners to Outperform adds some bullish sentiment to the overall neutral outlook.

Based on the available data and market analysis, here is the price prediction for GMAB stock in 2025:

GMAB is expected to reach $27-28 by end of 2025, supported by Leerink Partners' recent upgrade to Outperform with a $27 price target and the company's strong pipeline of late-stage drug candidates. The stock is currently trading at $22.53 with positive momentum, showing a +0.85% gain in today's regular market session, and technical indicators suggest an upward trend with RSI at 65.39 indicating moderate buying pressure.

The S1 support level for GMAB Stock is $20.58 ,The R1 resistant level for GMAB Stock is $23.01.

As of the end of day on 2025-02-27, the price of GMAB Stock was $22.65.

The target price for GMAB Stock according to analyst rating is 37.40, with the highest price target at 50.00 and the lowest at 27.00. Analysts have a Moderate Buy rating on GMAB Stock overall.

The market cap of GMAB is $1.5B.

Based on the provided data and current market conditions, here's a comprehensive analysis of whether GMAB is overvalued:

Technical Analysis GMAB is currently trading at $22.53 during regular market hours, showing a RSI-14 of 65.39 which indicates moderately overbought conditions but not extremely so. The stock is trading above its 5-day SMA ($21.96) and 10-day SMA ($20.70), suggesting short-term bullish momentum.

Valuation Metrics The stock's current valuation metrics show:

• Forward P/E: 3.26x (decreased from 3.56x in 2022)
• Forward EV/EBITDA: 20.37x (decreased from 26.12x in 2022)
• Forward P/S: 0.86x (decreased from 1.34x in 2022)
• Forward P/B: 0.44x (decreased from 0.71x in 2022)

Recent Analyst Actions According to recent analyst reports, Leerink Partners upgraded GMAB to Outperform with a $27 price target, suggesting the stock is currently undervalued at current levels around $22.53.

Conclusion GMAB is NOT overvalued based on its declining forward multiples, strong analyst support, and reasonable technical indicators. The stock's valuation metrics have improved significantly from 2022, while maintaining solid fundamentals and positive analyst sentiment.

Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

Based on the available data and market analysis, here is the price prediction for GMAB stock by 2030:

Technical Analysis & Current Position GMAB is currently trading at $22.53 with a clear downward trend since October 2024, having fallen from highs around $30. The stock shows significant technical weakness with RSI at 65.39, indicating slightly overbought conditions.

Growth Catalysts & Price Target The stock is expected to reach $35-40 by 2030, representing a ~60-80% upside from current levels. This projection is supported by:

1. Strong pipeline development and positive analyst sentiment, with Leerink Partners recently upgrading the stock to Outperform with a $27 price target.

2. The company's robust history in drug development and multiple late-stage candidates in its pipeline, which should drive long-term value creation.

3. Current technical weakness presents an attractive entry point for long-term investors, with strong support around $20 level.

The stock appears undervalued at current levels, trading at attractive multiples compared to biotech peers. The recent pullback from $30+ levels provides a good entry opportunity for long-term investors targeting the $35-40 range by 2030.

GMAB has a total of 2204 employees.